CRNX Crinetics Pharmaceuticals, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $6.51M on the open market; over its last four quarters it reported revenue of $42.2M and net income of −$502M.
CRNX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $25.1M, net income −$121M, EPS -1.14
- Quarter ended Mar 31, 2026: revenue $10.7M, net income −$128M, EPS -1.23
- Quarter ended Dec 31, 2025: revenue $6.16M, net income −$123M, EPS -1.30
- Quarter ended Sep 30, 2025: revenue $143K, net income −$130M, EPS -1.38
Recent CRNX insider trades
- Jul 2, 2026: Vivaldi Coelho Rogerio sold 3,000 shares ($120K)
- Jun 17, 2026: Okey Stephanie sold 6,900 shares ($246K)
- Apr 8, 2026: Knight Jeff E. sold 85,163 shares ($3.42M)
- Mar 16, 2026: Struthers Richard Scott sold 21,981 shares ($822K)
Members of Congress trading CRNX
- Jul 30, 2026: Gilbert Ray Cisneros, Jr. sold $15.0K–$50.0K
- Mar 3, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Apr 17, 2025: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Mar 19, 2025: Josh Gottheimer sold $1.00K–$15.0K
- Jan 29, 2025: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Sep 25, 2024: Josh Gottheimer bought $1.00K–$15.0K
5%+ owners
- Dapice Joshua J.: 8.5% (Schedule 13G/A, filed Feb 5, 2026)
- Farallon Capital Management, L.L.C.: 8.5% (Schedule 13G/A, filed Aug 3, 2026)
- Wellington Management Group LLP: 6.8% (Schedule 13G/A, filed Aug 13, 2026)
- DRIEHAUS CAPITAL MANAGEMENT LLC: 6.1% (Schedule 13G/A, filed May 15, 2026)
- Vanguard Capital Management: 5.2% (Schedule 13G, filed Apr 29, 2026)
- T. Rowe Price Associates, Inc.: 5.1% (Schedule 13G/A, filed May 15, 2026)
Are insiders buying or selling CRNX?
Over the last 12 months insiders bought $0 and sold $6.51M of Crinetics Pharmaceuticals, Inc. stock on the open market (SEC Form 4).
What was CRNX's revenue last quarter?
Crinetics Pharmaceuticals, Inc. reported revenue of $25.1M for the quarter ended June 30, 2026, with net income of −$121M.